Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
ABSTRACT Background Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment. Aims To...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.70117 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832577748335329280 |
|---|---|
| author | DENO Research Group Carolina de laCalva Manuel Angulo Paula González‐Rojo Ana Peiró Pau Machado Juan Luis Cebrián Roberto García‐Maroto Antonio Valcárcel Pablo Puertas Gregorio Valero‐Cifuentes Óscar Pablos Miriam Maireles María Luisa Fontalva Iván Chaves Aida Orce Luis Coll‐Mesa Israel Pérez Fausto González María delCarmen Sanz Isidro Gracia |
| author_facet | DENO Research Group Carolina de laCalva Manuel Angulo Paula González‐Rojo Ana Peiró Pau Machado Juan Luis Cebrián Roberto García‐Maroto Antonio Valcárcel Pablo Puertas Gregorio Valero‐Cifuentes Óscar Pablos Miriam Maireles María Luisa Fontalva Iván Chaves Aida Orce Luis Coll‐Mesa Israel Pérez Fausto González María delCarmen Sanz Isidro Gracia |
| author_sort | DENO Research Group |
| collection | DOAJ |
| description | ABSTRACT Background Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment. Aims To analyze the outcomes of patients diagnosed with GCTB and who had finished single treatment with denosumab. Methods and Results This is a multicenter, retrospective, descriptive study carried out in seven Spanish hospitals with multidisciplinary sarcoma and musculoskeletal tumor boards, between 2009 and 2019. Sixteen patients diagnosed with unresectable GCTBs and treated with denosumab who had reached the end of their treatment were recruited for the study and had been followed up for a minimum of 2 years. Fifty percent of patients discontinued denosumab after showing signs of tumor control. The disease remained stable in 69% of patients (n = 11), with a median recurrence‐free survival time of 46 months (20–157 months) after being treated for a median period of 19 months (5–83 months). Four patients experienced local progression, and one presented multifocal progression. These five patients were treated for a median period of 46 months (14–76 months), with a median recurrence‐free survival time of 9 months (5–25 months). Conclusion The findings of the present study suggest that discontinuation of denosumab in patients with unresectable GCTB is not necessarily associated with the progression of the disease. Further research is needed to determine how long denosumab should be administered to minimize the risk of recurrence. |
| format | Article |
| id | doaj-art-72e11f63e058411aadfcfb5922390644 |
| institution | Kabale University |
| issn | 2573-8348 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj-art-72e11f63e058411aadfcfb59223906442025-01-30T15:46:35ZengWileyCancer Reports2573-83482025-01-0181n/an/a10.1002/cnr2.70117Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?DENO Research GroupCarolina de laCalva0Manuel Angulo1Paula González‐Rojo2Ana Peiró3Pau Machado4Juan Luis Cebrián5Roberto García‐Maroto6Antonio Valcárcel7Pablo Puertas8Gregorio Valero‐Cifuentes9Óscar Pablos10Miriam Maireles11María Luisa Fontalva12Iván Chaves13Aida Orce14Luis Coll‐Mesa15Israel Pérez16Fausto González17María delCarmen Sanz18Isidro Gracia19Hospital Universitario y Politécnico La Fe Valencia SpainHospital Universitario y Politécnico La Fe Valencia SpainHospital Universitario y Politécnico La Fe Valencia SpainHospital de la Santa Creu i Sant Pau Barcelona SpainHospital de la Santa Creu i Sant Pau Barcelona SpainHospital Clínico San Carlos Madrid SpainHospital Clínico San Carlos Madrid SpainHospital Clínico Universitario Virgen de la Arrixaca Murcia SpainHospital Clínico Universitario Virgen de la Arrixaca Murcia SpainHospital Clínico Universitario Virgen de la Arrixaca Murcia SpainHospital Universitario de Bellvitge L'Hospitalet de Llobregat SpainHospital Universitario de Bellvitge L'Hospitalet de Llobregat SpainHospital Universitario de Bellvitge L'Hospitalet de Llobregat SpainHospital Universitario Nuestra Señora de Candelaria Santa Cruz de Tenerife SpainHospital Universitario Nuestra Señora de Candelaria Santa Cruz de Tenerife SpainHospital Universitario Nuestra Señora de Candelaria Santa Cruz de Tenerife SpainHospital Universitario Ramón y Cajal Madrid SpainHospital Universitario Ramón y Cajal Madrid SpainHospital Universitario Ramón y Cajal Madrid SpainHospital de la Santa Creu i Sant Pau Barcelona SpainABSTRACT Background Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment. Aims To analyze the outcomes of patients diagnosed with GCTB and who had finished single treatment with denosumab. Methods and Results This is a multicenter, retrospective, descriptive study carried out in seven Spanish hospitals with multidisciplinary sarcoma and musculoskeletal tumor boards, between 2009 and 2019. Sixteen patients diagnosed with unresectable GCTBs and treated with denosumab who had reached the end of their treatment were recruited for the study and had been followed up for a minimum of 2 years. Fifty percent of patients discontinued denosumab after showing signs of tumor control. The disease remained stable in 69% of patients (n = 11), with a median recurrence‐free survival time of 46 months (20–157 months) after being treated for a median period of 19 months (5–83 months). Four patients experienced local progression, and one presented multifocal progression. These five patients were treated for a median period of 46 months (14–76 months), with a median recurrence‐free survival time of 9 months (5–25 months). Conclusion The findings of the present study suggest that discontinuation of denosumab in patients with unresectable GCTB is not necessarily associated with the progression of the disease. Further research is needed to determine how long denosumab should be administered to minimize the risk of recurrence.https://doi.org/10.1002/cnr2.70117denosumabgiant cell tumors of bonerecurrenceunresectable |
| spellingShingle | DENO Research Group Carolina de laCalva Manuel Angulo Paula González‐Rojo Ana Peiró Pau Machado Juan Luis Cebrián Roberto García‐Maroto Antonio Valcárcel Pablo Puertas Gregorio Valero‐Cifuentes Óscar Pablos Miriam Maireles María Luisa Fontalva Iván Chaves Aida Orce Luis Coll‐Mesa Israel Pérez Fausto González María delCarmen Sanz Isidro Gracia Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment? Cancer Reports denosumab giant cell tumors of bone recurrence unresectable |
| title | Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment? |
| title_full | Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment? |
| title_fullStr | Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment? |
| title_full_unstemmed | Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment? |
| title_short | Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment? |
| title_sort | do unresectable giant cell tumors of bone treated with denosumab progress after discontinuation of treatment |
| topic | denosumab giant cell tumors of bone recurrence unresectable |
| url | https://doi.org/10.1002/cnr2.70117 |
| work_keys_str_mv | AT denoresearchgroup dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT carolinadelacalva dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT manuelangulo dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT paulagonzalezrojo dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT anapeiro dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT paumachado dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT juanluiscebrian dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT robertogarciamaroto dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT antoniovalcarcel dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT pablopuertas dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT gregoriovalerocifuentes dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT oscarpablos dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT miriammaireles dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT marialuisafontalva dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT ivanchaves dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT aidaorce dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT luiscollmesa dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT israelperez dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT faustogonzalez dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT mariadelcarmensanz dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment AT isidrogracia dounresectablegiantcelltumorsofbonetreatedwithdenosumabprogressafterdiscontinuationoftreatment |